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Summary
Anticancer agents that selectively kill tumor cells and spare normal tissues are urgently needed. Here, we engineered a
cell-permeable peptidomimetic, shepherdin, modeled on the binding interface between the molecular chaperone Hsp90
and the antiapoptotic and mitotic regulator, survivin. Shepherdin makes extensive contacts with the ATP pocket of Hsp90,
destabilizes its client proteins, and induces massive death of tumor cells by apoptotic and nonapoptotic mechanisms.
Conversely, shepherdin does not reduce the viability of normal cells, and does not affect colony formation of purified
hematopoietic progenitors. Systemic administration of shepherdin in vivo is well tolerated, and inhibits human tumor
growth in mice without toxicity. Shepherdin could provide a potent and selective anticancer agent in humans.S I G N I F I C A N C E
It has long been appreciated that tumor cells are “stressed” cells capable of coping with unfavorable environments via a general-
ized upregulation of their stress response machinery. This is largely centered on the expression and function of the molecular chaper-
one Hsp90, which has provided an attractive target for therapeutic intervention in cancer. Here, we report the structure-based
design and characterization of shepherdin, a novel peptidomimetic antagonist of the complex between Hsp90 and survivin, another
key regulator of tumor cell viability. For its potent and broad antitumor activity, selectivity of action in tumor cells versus normal
tissues, and inhibition of tumor growth in vivo without toxicity, shepherdin may offer a promising approach for rational cancer
therapy.Introduction
Despite a better understanding of the biology of tumor cells
(Vogelstein and Kinzler, 2004), the treatment of most cancers
has not significantly changed for the past three decades, and
drugs that do not discriminate between tumor cells and normal
tissues remain mainstays of anticancer therapy. Disabling an
essential oncogenic pathway has produced encouraging re-
sults in the management of certain malignancies (O’Dwyer and
Druker, 2000; Paez et al., 2004). However, this type of “tar-
geted” therapy may not be immediately applicable to most
solid tumors, in which the accumulation of numerous molecular
abnormalities (Vogelstein and Kinzler, 2004) and genomic insta-
bility (Sieber et al., 2003) may elude the identification of a sin-
gle, driving oncogene. Conversely, pathways that intersect
multiple essential functions of tumor cells may provide broader
therapeutic prospects. A candidate for such an approach is
survivin, an essential regulator of cell proliferation, differentia-
tion, and apoptosis that is sharply overexpressed in cancer
versus normal tissues, and frequently linked to unfavorable dis-
ease outcome (Altieri, 2003). Because of its role at a crossroad
of multiple cellular functions (Okada and Mak, 2004), and the
likelihood that survivin antagonists may have selective antitu-
mor efficacy in vivo (Altieri, 2003), drug discovery efforts toCANCER CELL : MAY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.target the survivin pathway in cancer are being vigorously pur-
sued, and clinical testing of survivin antisense oligonucleotides
has recently begun. A nodal point for the multiple functions of
survivin in tumor cells is its association with heat shock protein
90 (Hsp90), which is required to preserve survivin stability,
in vivo (Fortugno et al., 2003). Hsp90 is an ATPase-directed
molecular chaperone that oversees protein folding quality con-
trol during the cellular stress response, and whose repertoire
of client proteins is typically restricted to signaling molecules
involved in cell proliferation and cell survival (Young et al.,
2001). This is thought to play a key role in cancer, where Hsp90
is commonly upregulated, and its stress response recognition
may help promote tumor cell adaptation in face of unfavorable
environments (Isaacs et al., 2003). Conversely, this pathway
has created a viable therapeutic opportunity (Sausville et al.,
2003), and molecular targeting of Hsp90 ATPase activity by the
class of ansamycin antibiotics prototypically exemplified by
Geldanamycin (GA) (Neckers and Ivy, 2003) has shown promis-
ing anticancer activity for disabling multiple signaling networks
required for tumor cell maintenance (Basso et al., 2002).
Here, we used structure-based mimicry to disrupt the sur-
vivin-Hsp90 interaction, and test its suitability as a novel drug
target in cancer.DOI 10.1016/j.ccr.2005.03.035 457
A R T I C L EResults
Identification of shepherdin
Using synthetic peptidyl mimicry, we recently identified a sur-
vivin sequence K79–K90, which blocks the interaction between
survivin and Hsp90, in vitro (Fortugno et al., 2003). By surface
plasmon resonance, the survivin K79–K90 peptide bound
Hsp90 with high affinity (KD ± SEM = 8.38 x 10−8 ± 3.5−9 M)
at increasing ligand concentrations (0.1–10 M). Conversely, a
mutant C84/A peptide (see below) did not bind Hsp90, and
exhibited a 10-fold increased off-rate as compared with the
wild-type sequence, as shown by surface plasmon resonance.
To narrow the minimal interacting region in K79–K90, we tested
variant peptides, and found that the sequence I74–L87 re-
tained the ability to bind Hsp90 in vivo with its associated
chaperone Hsp70, but not Hsp27, by affinity chromatography
of B lymphoma Raji cell extracts (Figure 1A). Therefore, the
minimal survivin sequence K79–L87 was named shepherdin for
its binding to the “shepherding” chaperone Hsp90. To test
whether shepherdin disrupted the survivin-Hsp90 complex in aFigure 1. Identification of shepherdin
A: Affinity chromatography. S100 Raji cell extracts were fractionated over
control resin or immobilized survivin peptide I74–L87. Flow-through (FT) or
eluted (E) material was analyzed by Western blotting.
B: Inhibition of survivin-Hsp90 interaction. Aliquots of rabbit reticulocyte ex-
tracts were left untreated or incubated with shepherdin or scrambled pep-
tide, mixed with recombinant survivin, and immunoprecipitated with con-
trol IgG or an antibody to Hsp90. The immune complexes were analyzed
by Western blotting.
C: Peptide competition of Hsp90-ATP binding. Recombinant Hsp90 N do-
main was mixed with soluble ATP, shepherdin, or scrambled peptide and
incubated with γ-phosphate-linked ATP-sepharose, and bound material
was eluted in 5% SDS and analyzed by Western blotting.
D: Peptide mutagenesis. Wild-type or mutant shepherdin peptides were
immobilized on plastic microtiter plates and Hsp90 binding was detected
by ELISA. Data are the mean ± SD of two independent experiments. WT,
wild-type shepherdin.458cellular context, we reconstituted this interaction in reticulocyte
extracts, which have been used before to assemble functional
Hsp90 complexes (Morishima et al., 2000). Recombinant sur-
vivin added to untreated reticulocyte extracts formed a com-
plex with endogenous Hsp90, as detected by coimmunopreci-
pitation and Western blotting (Figure 1B). In contrast, a control
IgG did not immunoprecipitate survivin from reticulocyte ex-
tracts (Figure 1B). Preincubation of reticulocyte extracts with
shepherdin completely inhibited the association of recombi-
nant survivin with Hsp90, whereas a scrambled peptide had
minimal effect (Figure 1B). Next, we asked whether shepherdin
interfered with ATP binding to Hsp90 (Marcu et al., 2000). Addi-
tion of a scrambled peptide to recombinant N-domain of
Hsp90 (residues 1–272) did not affect binding to ATP-sepha-
rose, as shown by affinity chromatography (Figure 1C). In con-
trast, shepherdin blocked the interaction between N-Hsp90
and immobilized ATP, which was also fully competed out by
addition of soluble ATP (Figure 1C). To map the requisites of
shepherdin binding to Hsp90, we generated mutant peptides
with single amino acid substitutions. Mutagenesis of H80, S81,
S82, G83, and C84 abolished shepherdin binding to Hsp90,
whereas substitution of K79, A85, F86, or L87 had no effect
(Figure 1D). In the survivin crystal structure, amino acids H80–
G83 form a flexible loop connecting the fourth and fifth α heli-
ces of the baculovirus IAP repeat, and H80 contributes to a
surface-exposed “basic patch” (Verdecia et al., 2000).
Structural analysis of shepherdin
Several shepherdin variants were synthesized for further exper-
iments, including a retro-inverso peptidomimetic analog desig-
nated shepherdin-RV (inverse sequence L79–K87, all D amino
acids). The structures of shepherdin and shepherdin-RV were
studied in solution by long time scale molecular dynamics (MD)
simulations in explicit water solvent (Supplemental Data and
Supplemental Table S1). Analysis of the trajectories predicts
that both shepherdin and shepherdin-RV have a dominant con-
figuration characterized by a turn involving S82–G83 in shep-
herdin and G83–S84 in shepherdin-RV, and overall β-hairpin
geometry (Figure 2A). The most populated conformation of
shepherdin-RV shows a higher degree of compactness, with
the aromatic ring of F80 packing on the turn region (Figure 2A).
The representative β-hairpin conformations of shepherdins
were subjected to multiple docking experiments on Hsp90
using the AutoDock program package (Morris et al., 1998). In
all cases, the peptides were predicted to dock into the ATP
binding site of Hsp90 (Figures 2B and 2C). The geometry of
the final complex is highly correlated with that of the complex
between Hsp90 and GA (Stebbins et al., 1997), with the turn
region of the peptides closely tracing the ansa ring backbone
of GA (Figures 2D and 2E). Shepherdin and shepherdin-RV
make 13 and 18 predicted hydrogen bonds with the ATP
pocket of Hsp90, respectively, involving the side chains of H80,
S81, S82, the carbonyl group of G83, and the side chains of
K87 and C82 (shepherdin-RV). Except for D93, the comple-
mentary residues of Hsp90 predicted to make contact with
shepherdin and/or shepherdin-RV largely overlap with amino
acids implicated in GA binding (Stebbins et al., 1997), including
S113, which has been recently shown to contribute to stepwise
accessibility of the ATP pocket of Hsp90 to GA (Lee et al.,
2004). Shepherdin and shepherdin-RV are predicted to assume
more extended conformations than GA in the Hsp90 pocketCANCER CELL : MAY 2005
A R T I C L EFigure 2. Structural analysis of shepherdin
A: Predictive representative structure of the
most populated conformational cluster of shep-
herdin-RV as calculated from statistical analysis
of MD trajectories.
B and C: Two orthogonal views of the dominant
structure of shepherdin-RV (ribbon) as obtained
by MD simulations are shown overlaid onto the
crystal structure of Hsp90.
D and E: Two orthogonal views of shepherdin-RV
(red ribbon) in complex with Hsp90 as obtained
by docking simulations. The peptide is overlaid
onto the crystal structure of GA (yellow) in com-
plex with Hsp90.
F: Hsp90 mutagenesis. The indicated mutants of
the N domain of Hsp90 were tested for binding
to shepherdin or scrambled peptide. Data are
the mean ± SEM of three independent experi-
ments. WT, wild-type N-Hsp90.(Figures 2D and 2E), and bury a solvent accessible surface of
498 and 546 Å2, respectively, as opposed to 402 Å2 buried
by GA.
To check these structural predictions, and validate experi-
mentally that shepherdin engaged Hsp90 differently from GA,
we introduced targeted mutations in the ATP pocket of Hsp90,
and tested their effect on shepherdin binding. Individual substi-
tution of N51, S52, D102, or S113 in the N domain of Hsp90
reduced binding to shepherdin by 20%–60%, whereas muta-
genesis of “GA-specific” D93 had no effect, and a scrambled
peptide did not bind wild-type or mutant Hsp90 (Figure 2F).
Molecular requirements of shepherdin-Hsp90 recognition
We next tested the interaction of shepherdin with individual do-
mains of Hsp90, and we first analyzed the middle domain (M)
for its role in client protein loading (Meyer et al., 2003). Blind
docking of shepherdin-RV to the three-dimensional structure
of the Hsp90 M domain did not reveal an organized binding
pocket, as shown by MD simulations (Figures 3A and 3B). As
compared with the extensive network of stabilizing contacts
observed for the N domain (Figures 2B–2E), shepherdin-RV
docked only to superficial regions of the M domain, mainly
through H bonding and electrostatic interactions (Figures 3A and
3B), and buried a considerably smaller surface area (410 Å2).CANCER CELL : MAY 2005Next, we compared the direct binding of shepherdin to recom-
binant N or C domain of Hsp90. Shepherdin associated with
the N domain Hsp90 in a concentration-dependent and satura-
ble manner (Figure 3C). In contrast, no specific binding of
shepherdin to the C domain of Hsp90 was demonstrated, as
compared with scrambled peptide (Figure 3C).
Intracellular delivery of shepherdin induces
tumor cell death
Cell-permeable variants of shepherdin were generated by fus-
ing the peptide N termini to either helix III of the Antennapedia
homeodomain protein (shepherdinAtp) (Kabouridis, 2003) or the
HIV-Tat sequence (shepherdinTat). Both cell-permeable shep-
herdin variants as well as their control scrambled sequences
rapidly (<1 hr) accumulated inside 100% of cervical carcinoma
HeLa cells (Figure 4A), and showed identical efficiency of intra-
cellular penetration in single cell fluorescence analysis (Figure
4B). In contrast, shepherdin or a scrambled peptide lacking cell
penetrating sequences did not accumulate intracellularly, as
shown by fluorescence microscopy (Figure 4A). Comparable
confluency of the various cell cultures used in these studies
was confirmed by light microscopy (not shown). The IC50 of
intracellular penetration for shepherdinAtp was 50–75 M, and
25–30 M for shepherdinTat, with the extent of intracellular ac-459
A R T I C L EFigure 3. Specificity of shepherdin-Hsp90 inter-
action
A and B: Two orthogonal views of shepherdin
(red) in association with the M domain of Hsp90
obtained by MD docking simulations.
C: Domain-specific interactions. Increasing con-
centrations of shepherdin or scrambled peptide
were immobilized on microtiter wells and incu-
bated with recombinant Hsp90 N or C domain,
and protein binding was detected with do-
main-specific antibodies by ELISA. Data are the
mean ± SEM of four independent experiments.cumulation decreasing sharply at lower peptide concentrations
(not shown). Next, we looked at the effect of intracellular deliv-
ery of shepherdin, and for all subsequent studies shepherdinAtp
was used unless otherwise specified. Treatment of HeLa cells
with increasing concentrations of shepherdin resulted in cata-
strophic loss of cell viability, with the entire cell population
exhibiting hypodiploid DNA content, as shown by propidium
iodide staining and flow cytometry (Figure 4C). In contrast, a
cell-permeable scrambled peptide, or shepherdin peptides
without cell penetrating sequences, were without effect (Figure
4C and not shown). In clonogenic assays, cell-permeable
shepherdin, but not a scrambled peptide, completely abolished
colony formation in soft agar (not shown). To identify the mech-
anism(s) by which shepherdin killed tumor cells, we examined
activation of nonapoptotic and apoptotic cell death pathways.
Treatment of HeLa cells with shepherdinAtp or shepherdinTat re-
sulted in rapid loss of plasma membrane integrity, with the en-
tire cell population becoming Trypan blue-positive by 3–6 hr
after peptide addition (Figure 4D). Within the same time frame,
shepherdin also induced activation of mitochondrial apoptosis,
with release of mitochondrial cytochrome c in the cytosol (Fig-
ure 4E). This was accompanied by typical hallmarks of apopto-
sis, including appearance of annexin V-labeled cells, and ex-
pression of caspase activity, as shown by multiparametric flow
cytometry (Figure 4F). Preincubation of HeLa cells with a cas-
pase inhibitor, ZVAD-fmk (20 M), only partially attenuated cell
death induced by shepherdin (64.6 ± 10% cell death versus
82.6 ± 4.4% at 125 M shepherdin, n = 3). Identical results
were obtained with cell-permeable shepherdin-RV, which also
induced loss of plasma membrane integrity and caspase acti-
vation in tumor cells (not shown). Conversely, intracellular ac-
cumulation of cell-permeable native or retro-inverso scrambled460peptides had no effect on tumor cell viability (Figures 4C–4F
and not shown).
Shepherdin inhibits Hsp90 chaperone function
A potential model to explain these findings is that shepherdin
engagement of the ATP pocket of Hsp90 (Figures 2B–2F) de-
stabilizes its client proteins, resulting in the acute breakdown
of multiple cell survival pathways (Isaacs et al., 2003), including
survivin (Fortugno et al., 2003). To test this prediction, we ex-
amined the levels of Hsp90 client proteins after intracellular
loading of shepherdin or scrambled peptide. Prostate carci-
noma PC3 cells treated with shepherdin exhibited loss of multi-
ple Hsp90 client proteins, including survivin, Akt, CDK-4, and
CDK-6, as shown by Western blotting (Figure 5A and not
shown). In contrast, shepherdin did not affect the levels of
Hsp90, Hsp70, or PCNA, and a cell-permeable scrambled pep-
tide did not modulate chaperone or client protein expression
(Figure 5A). We also tested the effect of shepherdin on telome-
rase activity, which requires Hsp90 (Holt et al., 1999). TRAP
analysis of Hsp90 immunoprecipitates from PC3 cells revealed
that shepherdin treatment almost completely abrogated the
enzyme’s catalytic activity, as compared with untreated or
scrambled peptide-treated cells (Figure 5B). Because of the
structural and functional similarities between shepherdin and
small molecule Hsp90 antagonist(s), e.g., GA, we compared
the antitumor efficacy of shepherdin with that of 17-AAG, a
derivative of GA currently in the clinic (Sausville et al., 2003). A
5 hr shepherdin treatment of various tumor cell lines resulted
in dose-dependent and complete cell killing (Figure 5C). In
contrast, 17-AAG had no effect on tumor cell viability within
this time frame (Figure 5C). With a prolonged incubation up
to 24 hr, the highest concentration of 17-AAG tested (10 M)CANCER CELL : MAY 2005
A R T I C L EFigure 4. Shepherdin-mediated cell killing
A: Intracellular penetration. HeLa cells were incubated with biotin-conjugated shepherdin (150 M), cell-permeable shepherdinAtp (150 M), cell-perme-
able shepherdinTat (50 M), or their respective scrambled peptides at comparable concentrations, labeled with PE-streptavidin, and analyzed by fluores-
cence microscopy.
B: Single cell analysis. Twenty-five randomly selected cells were analyzed for fluorescence intensity after incubation with shepherdinAtp or scrambled
peptide.
C: DNA content analysis. HeLa cells were treated with shepherdinAtp or scrambled peptide, harvested after 18 hr, and analyzed for DNA content by PI
staining and flow cytometry.
D: Loss of plasma membrane integrity. HeLa cells were incubated with shepherdinAtp (150 M), shepherdinTat (50 M), or cell-permeable scrambled
peptides at identical concentrations, stained for Trypan blue exclusion after 4 hr, and analyzed by light microscopy.
E: Cytochrome c release. Cytosolic extracts isolated from HeLa cells treated with shepherdinAtp or scrambled peptide (150 M) for 3 hr were analyzed by
Western blotting. COX-IV was used as a mitochondrial marker. Staurosporine (1 M for 16 hr) was used as a control for an apoptotic stimulus.
F: Induction of apoptosis. Cells incubated with shepherdinAtp or scrambled peptide (150 M) were analyzed after 5 hr by dual-color flow cytometry for
Annexin V labeling (HeLa cells, upper panel), or after 12 hr for caspase activity by DEVDase activity (MCF-7 cells, lower panel) in the green channel, and
PI staining in the red channel. The percentage of cells in each quadrant is indicated.producedw50% cell death (Figure 5C), thus confirming its an-
titumor activity (Basso et al., 2002).
Requirements of shepherdin-induced tumor cell killing
Tumors with low proliferative index that have lost the p53 tumor
suppressor gene, or that upregulate antiapoptotic mecha-
nisms, notably Bcl-2, are likely to become resistant to conven-
tional anticancer therapy (Johnstone et al., 2002), and to evade
checkpoint-based “targeted” therapy (Vassilev et al., 2004).
Therefore, it was of interest to test whether these conditions
affected shepherdin-mediated antitumor activity. Treatment of
a panel of tumor cell lines with shepherdin resulted in compara-
ble levels of cell killing whether cells were actively proliferating
or made quiescent by prior serum starvation (Figure 6A). Sec-
ondly, shepherdin was equally effective at inducing caspase-
dependent apoptosis and loss of plasma membrane integrityCANCER CELL : MAY 2005in p53+/+ or p53−/− HCT116 cells (Figure 6B). Lastly, overex-
pression of Bcl-2 in HeLa cells using a replication-defective
adenovirus effectively counteracted apoptosis induced by
staurosporine, but did not reduce shepherdin-mediated cell
killing (Figure 6C). In all experiments, a cell permeable scram-
bled peptide was without effect (Figures 6A–6C).
Selectivity of shepherdin antitumor activity
One of the pivotal objectives of “targeted” cancer therapy is to
selectively eliminate tumor cells while sparing normal tissues.
Therefore, we asked whether shepherdin was a selective anti-
cancer agent, discriminating between normal and tumor cells.
When added to prostate carcinoma (PC3, DU145) or HeLa
cells, shepherdin caused concentration-dependent and com-
plete loss of cell viability (Figure 7A), consistent with the data
presented above. In contrast, identical concentrations of shep-461
A R T I C L EFigure 5. Shepherdin inhibits Hsp90 chaperone function
A: Loss of Hsp90 client proteins. PC3 cells were left untreated or incubated
with shepherdinAtp or scrambled peptide (100 M) for 16 hr and analyzed
by Western blotting.
B: Telomerase activity. Hsp90 was immunoprecipitated from peptide-
treated PC3 cells and telomerase activity was determined by TRAP assay.
R8, external quantitative standard; ITAS, internal amplification standard.
C: Comparison with 17-AAG. The indicated tumor cell lines were treated
with shepherdinAtp or 17-AAG and analyzed for cell viability after 5 or 24 hr
by MTT.herdin did not reduce the viability of normal human fibroblasts
of three different tissue origins (Figure 7A), and a cell-perme-
able scrambled peptide had no effect on normal or tumor cells
(Figure 7A). Similarly, shepherdin did not reduce the viability of
nontransformed mouse embryonic fibroblasts (MEF), whereas
it efficiently killed JC mouse mammary carcinoma cells (Figure
7B). Because one of the most serious complications of con-
ventional cancer therapy is the ablation of bone marrow func-
tions, and survivin has been reported to play a role in progeni-
tor cell differentiation (Fukuda et al., 2004), we isolated human
CD34+ hematopoietic progenitor cells, and tested the effect of
shepherdin on their colony-forming ability. Treatment of purified
CD34+ progenitor cells with concentrations of shepherdin suffi-
cient to ablate tumor cell viability (see above) did not signifi-
cantly reduce colony formation along the erythroid or myeloid
lineage, as compared with scrambled peptide-treated cultures
(Figure 7C).
Hsp90 has been reported to bind ATP pocket inhibitors, i.e.,
17-AAG, with a w100-fold higher affinity in tumor cells as op-
posed to normal tissues, and this high-affinity conformation
may enhance the tumor selectivity of Hsp90 antagonists (Ka-
mal et al., 2003). To test whether shepherdin also differentially
bound Hsp90 from normal or tumor cells, we carried out affinity
chromatography experiments. Fractionation of B lymphoma
Raji cell extracts over shepherdin-sepharose resulted in the
isolation of Hsp90, and coelution of Hsp70, as shown by West-462ern blotting (Figure 7D), and in agreement with the data pre-
sented above (Figure 1A). In contrast, chromatography of nor-
mal peripheral blood mononuclear cell (PBMC) extracts over
shepherdin-sepharose did not yield immunoreactive bands, in-
dicating that shepherdin has little, if any, affinity for Hsp90 in
normal cells, and no independent recognition for Hsp70 (Figure
7D). In addition, silver staining analysis of shepherdin-bound
material eluted from Raji cell extracts revealed the presence of
only two main bands ofw70 andw90 kDa, demonstrating that
shepherdin specificity in vivo is highly restricted (Figure 7E).
Antitumor activity of shepherdin in vivo
To test the efficacy of shepherdin in human cancer models, we
first grew prostate carcinoma PC3 cells as superficial tumors
in immunocompromised mice, and started treatment when tu-
mors became palpable (w35–70 mm3). For these studies,
shepherdin-RV was used. Control animals given saline exhib-
ited progressive tumor growth during an 11-day interval (Figure
8A). Conversely, administration of shepherdin-RV (50 mg/kg,
i.p., daily) nearly completely ablated tumor growth (Figure 8A).
Within 1 hr of injection, shepherdin-RV accumulated in the tu-
mor mass, by fluorescence microscopy, whereas tumors of sa-
line-injected animals had only background fluorescence (Figure
8B). Secondly, we tested shepherdin-RV in a breast cancer xe-
nograft model that employs MCF-7 cells adapted in vivo. Injec-
tion of these cells in immunocompromised animals resulted in
exponentially growing tumors independently of estrogen sup-
plementation, which was unaffected by saline administration
(Figure 8C). Conversely, treatment with shepherdin-RV (50 mg/
kg i.p. daily) uniformly inhibited the growth of these more ag-
gressive tumors (p = 0.01) throughout a 23-day (Figure 8C) or
11-day treatment regimen (not shown). Blood samples taken
at the end of treatment revealed no alterations in cell counts or
blood chemistry in shepherdin- versus saline-treated animals
(Supplemental Table S2). In addition, histologic examination of
lung, spleen, and liver was equally unremarkable in the saline
or shepherdin group, and extramedullary hematopoiesis in the
spleen red pulp occurred with comparable frequency in control
or shepherdin-treated mice (Figure 8D). To test whether shep-
herdin caused loss of Hsp90 client proteins in the context of
the tumor mass in vivo, we analyzed MCF-7 tumors recovered
at the end of treatment. Tumors from the saline group exhibited
extensive labeling for survivin and Akt in the majority of the
tumor cell population, as shown by immunohistochemistry
(Figure 8E), in agreement with previous observations (Altieri,
2003; Basso et al., 2002). Conversely, shepherdin treatment re-
sulted in nearly complete loss of Akt levels in tumor cells
(Basso et al., 2002), and severely attenuated expression of sur-
vivin (Figure 8E). Similar results were obtained by Western blot-
ting analysis of tumor cell extracts, with considerable reduction
of survivin and Akt levels after shepherdin treatment, as com-
pared with the saline group (Figure 8F).
Discussion
In this study, we used structure-based rational prediction to
identify and characterize shepherdin, a novel anticancer pepti-
domimetic modeled on the survivin-Hsp90 binding interface
(Fortugno et al., 2003). Shepherdin engages the ATP pocket of
Hsp90 with unique binding characteristics, destabilizes sur-
vivin plus several additional client proteins, and causes mas-CANCER CELL : MAY 2005
A R T I C L EFigure 6. Requirements of shepherdin antitumor
activity
A: Independence of cell cycle progression. Tu-
mor cell lines (squares, HeLa; circles, MCF-7; up-
ward triangles, PC3; downward triangles, H-460)
were made quiescent by 24 hr serum starvation
(quiescent), or maintained in complete growth
medium (proliferating), treated with shep-
herdinAtp (closed symbols) or scrambled pep-
tide (open symbols), and analyzed after 5 hr by
MTT. Data are the mean ± SEM of four experi-
ments.
B: p53 independence. p53+/+ or p53−/− HCT116
cells were treated with shepherdinAtp or scram-
bled peptide (150 M) for 12 hr, and analyzed
for caspase activity (DEVDase activity) and loss
of plasma membrane integrity by PI staining, by
multiparametric flow cytometry. The percen-
tage of cells in each quadrant is indicated.
C: Bcl-2 independence. Untreated (no virus) or
HeLa cells transduced with an adenovirus en-
coding Bcl-2 (pAd-Bcl-2) were incubated with
the indicated concentrations of shepherdinAtp,
scrambled peptide, or a shepherdinAtp S81A mutant peptide that does not bind Hsp90 (Figure 1C), and analyzed after 12 hr by MTT. Bcl-2 cytoprotection
from staurosporine (STS)-induced apoptosis (1 M) was used as a control.sive killing of tumor cells by apoptotic and nonapoptotic mech-
anisms. Shepherdin is selective in its antitumor activity, and
does not affect the viability of normal cells or tissues, including
human hematopoietic progenitors. When administered in vivo,
shepherdin is safe and well tolerated, and inhibits growth of
different tumor cell types without systemic or organ toxicity.
Taken together, these features may make shepherdin an attrac-
tive lead prodrug for “targeted” cancer therapy.
Although initially designed as a high-affinity (KD w80 nM)
inhibitor of the survivin-Hsp90 interaction, the data presented
here suggest that shepherdin may function as a more global
antagonist of Hsp90 chaperone activity. This conclusion is
based on the structure-function analysis of shepherdin, and in
particular its ability to expansively engage the chaperone ATP
pocket, compete for the Hsp90-ATP complex, and destabilize
multiple Hsp90 client proteins in addition to survivin, in vivo.
Because of these features, shepherdin appears ideally suited
to interfere with the periodicity of Hsp90 ATPase cycles, by
directly preventing ATP binding (Stebbins et al., 1997), and/or
by competing with cochaperone recruitment, especially that of
p50cdc37, which is required for ATPase activity and shares over-
lapping binding contacts with shepherdin (Roe et al., 2004). In
this context, the simultaneous destabilization of survivin levels
(Altieri, 2003), combined with the acute collapse of Hsp90
function (Isaacs et al., 2003), would be expected to cause a
general breakdown of multiple cell proliferation and cell survival
pathways in tumor cells, suitable for therapeutic exploitation
(Neckers and Ivy, 2003).
Consistent with this model, a brief exposure of disparate tu-
mor cell lines to cell-permeable variants of shepherdin resulted
in massive and complete cell killing via activation of nonapo-
ptotic and apoptotic mechanisms, the latter involving mito-
chondrial dysfunction, i.e., permeability transition. The concen-
trations of shepherdin needed to achieve complete tumor cell
killing (IC50w25–75 M, depending on the cell penetrating se-
quence), are in line with those of previous studies using cell-
permeable carrier sequences (Chen et al., 1999; Sawada et al.,CANCER CELL : MAY 20052003), and reflect the efficiency of intracellular penetration
rather than the affinity of the mimetic for the target. The ability
of shepherdin to trigger both apoptotic and nonapoptotic cell
death may explain its broad antitumor activity, which indistin-
guishably affected tumor cell types of different derivations, re-
gardless of their proliferative condition (Swanton, 2004), p53
status (Vogelstein et al., 2000), or overexpression of potent sur-
vival signals, e.g., Bcl-2 (Johnstone et al., 2002), all conditions
that typically compromise the efficacy of conventional or
“targeted” anticancer therapy (Vassilev et al., 2004). In addi-
tion, shepherdin kills tumor cells far more rapidly and more po-
tently than other Hsp90 antagonists currently in the clinic, e.g.,
17-AAG (Sausville et al., 2003). As demonstrated by affinity
chromatography, this higher antitumor efficacy of shepherdin
can not be explained with nonspecific recognition of multiple
cellular proteins, and does not involve an independent specific-
ity for Hsp70, a regulator of mitochondrial apoptosis and cas-
pase-independent cell death (Beere, 2004). Conversely, it
seems plausible that by virtue of its unique binding interface
with Hsp90, shepherdin may disrupt additional, and potentially
as yet unrecognized, cell survival functions of the chaperone
that are not efficiently compromised by GA or 17-AAG.
When tested as an anticancer agent in tumor models, shep-
herdin was selective and well-tolerated, sparing normal cells,
preserving colony-forming ability of purified human hematopoi-
etic progenitors, and causing no organ or systemic toxicity af-
ter prolonged administration in vivo. This desirable selectivity
may involve the differential overexpression of survivin and
Hsp90 in tumors as opposed to normal tissues (Altieri, 2003;
Isaacs et al., 2003), as well as qualitative changes in Hsp90,
which exhibits a w100-fold higher affinity for binding ATP
pocket antagonists in tumor versus normal cells. Previously
demonstrated for 17-AAG (Kamal et al., 2003), a similar para-
digm can be extended to shepherdin, which bound avidly to
Hsp90 in lymphoma cells, but not at all in normal human mono-
nuclear cells.
In summary, shepherdin has the molecular features of both463
A R T I C L EFigure 7. Selectivity of shepherdin-mediated
cell killing
A: The indicated tumor or normal cell lines were
incubated with shepherdinAtp or scrambled
peptide, and analyzed for cell viability after 3 hr
by MTT.
B: Analysis of embryonic cells. Mouse embryonic
fibroblasts (MEF) or JC mouse mammary carci-
noma cells were treated with shepherdinAtp or
scrambled peptide, and analyzed by Trypan
blue exclusion. Data are the mean ± SEM of
three independent experiments.
C: Hematopoietic progenitor colony formation
assay. Purified human CD34+ hematopoietic
progenitor cells were incubated with shep-
herdinAtp or scrambled peptide for 2.5 hr and
plated in semisolid medium with cytokines, and
colonies were scored after 10–12 days. CFU-E,
colony-forming unit, erythroid; BFU-E, burst-form-
ing unit, erythroid; CFU-GM, colony-forming unit,
granulocyte-macrophage; CFU-M, colony-form-
ing unit, macrophage; CFU-GEMM, colony-
forming unit, granulocyte, erythroid, macro-
phage. Data are the mean ± SD of 2 individual
replicates.
D: Affinity chromatography. Extracts from B lym-
phoma Raji cells or freshly isolated normal PBMC
were fractionated over shepherdin-sepharose,
and eluted material was analyzed by Western
blotting. WCE, whole cell extracts.
E: Silver staining. The experimental conditions
are the same as in D, except that fractions
eluted from Raji cell extracts over shepherdin-
sepharose were analyzed by silver staining.
WCE, whole cell extracts.an inhibitor of a critical protein-protein interaction in tumor
cells, e.g., survivin-Hsp90 (Fortugno et al., 2003), and an enzy-
matic antagonist of Hsp90 ATPase cycles (Isaacs et al., 2003).
Because of these combined features, plus its considerably
higher potency compared to other Hsp90 inhibitors, e.g., 17-
AAG, shepherdin may provide a potent and selective new anti-
cancer agent in humans, consistent with the use of peptidomi-
metics in targeted cancer therapy (Guillemard and Saragovi,
2004). In addition, we narrowed the shepherdin binding inter-
face to a short stretch of amino acids between H80 and C84
in the survivin sequence. Previously, mutagenesis of H80
(Muchmore et al., 2000) or C84 (Li et al., 1998) resulted in do-
minant negative phenotypes with mitotic defects and induction
of apoptosis in tumor cells, thus further underscoring their criti-
cal roles in survivin function. This small cluster of residues may
thus provide a manageable platform for further derivatization
of shepherdin, as well as for chemical screenings to identify
shepherdin-like small molecules with enhanced, “targeted” an-
ticancer activity in humans.
Experimental procedures
Cells and cell cultures
The following human normal or tumor cell lines were obtained from the
American Type Culture Collection (ATCC), and maintained in culture as re-
commended by the supplier: foreskin fibroblasts HFF, gingival fibroblasts464HGF, skin fibroblasts WS-1, prostate adenocarcinoma PC3 and DU145,
breast carcinoma MCF-7, B lymphoma Raji, non-small cell lung carcinoma
H-460, and cervical carcinoma HeLa. The redesignated melanoma cell line
MDA-MB-435LCC6 was kindly provided by Dr. M. Bally (Vancouver, Can-
ada), and p53+/+ or p53−/− HCT116 colorectal carcinoma cells were kindly
provided by Dr. B. Vogelstein (Baltimore, MD). Mouse embryonic fibroblasts
(MEF) and mammary carcinoma JC cells were also obtained from ATCC.
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized
blood obtained from healthy volunteers after informed consent by Ficoll-
Hypaque gradient density centrifugation.
Peptide synthesis and recombinant protein expression
All peptides were synthesized by the W.M. Keck Biotechnology Research
Center at Yale University School of Medicine using solid phase tBoc chem-
istry, followed by reverse-phase high-pressure liquid chromatography, mass
spectrometry, and solid phase purification. Peptides were dissolved in
water and buffered to pH 7.4. Peptide solutions were prepared fresh every
time immediately prior to use, and were not stored. The survivin sequence
K79–L87 (KHSSGCAFL, shepherdin) was made cell-permeable by addition
of helix III of the cell-penetrating Antennapedia homeodomain sequence
(underlined) (Kabouridis, 2003), as follows: free/biotin-RQIKIWFQNRRMK
WKKKHSSGCAFL-COOH (shepherdinAtp). A corresponding control scram-
bled peptide was free/biotin-RQIKIWFQNRRMKWKKSKLACFSHG-COOH.
A second carrier sequence derived from the HIV Tat protein (Chen et al.,
1999) (underlined) and fused at the peptide N termini was also used as
follows: biotin-X-YGRKKRRQRRRKHSSGCAFL-CONH2 (shepherdinTat). A
control scrambled peptide using the HIV Tat protein (underlined) was also
synthesized as: biotin-X-YGRKKRRQRRRSKLACFSHG-CONH2. X = EAHX,
hexanoic acid spacer. Mutant peptides of the shepherdin sequence carryingCANCER CELL : MAY 2005
A R T I C L EFigure 8. Shepherdin inhibits tumor growth in vivo
A: Kinetics of prostate cancer xenograft growth. SCID/beige mice carrying human PC3 xenograft tumors were treated with daily i.p. injections of saline or
cell permeable shepherdin-RV (50 mg/kg) for the indicated time intervals (5/6 animals/group). Tumor volume was measured with a caliper. Data are
expressed as mean ± SEM.
B: Intratumor accumulation. Animals were injected i.p. with saline or biotin-shepherdin-RV and sacrificed after 1 hr, and frozen tumor sections were stained
with streptavidin-conjugated PE, and analyzed by phase (upper panels) or fluorescence (lower panels) microscopy.
C: Kinetics of breast cancer xenograft growth. SCID/beige mice carrying xenograft tumors from MCF-7 cells adapted in vivo were injected i.p. with saline
or cell-permeable shepherdin-RV (50 mg/kg/daily) (6 animals/group) for the indicated time intervals. Each line corresponds to the kinetics of tumor growth
of an individual animal.
D: Histology. Formalin-fixed paraffin-embedded tissue sections of liver, spleen or lung from saline- or shepherdin-treated animals were stained by hematoxy-
lin/eosin, and analyzed by light microscopy.
E: Loss of Hsp90 client proteins after shepherdin treatment in vivo. MCF-7 xenografts from saline- or shepherdin-treated animals were harvested at the end
of treatment and analyzed with antibodies to survivin or Akt by immunohistochemistry.
F: Western blotting. MCF-7 tumors harvested at the end of saline or shepherdin-RV treatment were analyzed by Western blotting.single amino acid substitutions at each position were also synthesized. Ev-
ery residue was mutated to Ala except Ala85, which was changed to Gly. A
cell-permeable “retro-inverso” (Pescarolo et al., 2001) shepherdin peptide
(shepherdin-RV) fused to the Antennapedia sequence was synthesized
using Fmoc chemistry and solid phase purification using all D amino acids
in the reverse orientation (Herve et al., 1997; Hong et al., 1999), and with
Val substituting Ile in the Antennapedia sequence (Brugidou et al., 1995) as
follows: biotin-X-KKWKMRRNQFWVKVQRLFACGSSHK-CONH2. A control
scrambled RV peptide was biotin-X-KKWKMRRNQFWVKVQRGHSFCALKS-CANCER CELL : MAY 2005CONH2. X = EAHX, hexanoic acid spacer. Individual recombinant Hsp90
domains (N domain, residues 1–272; M domain, residues 273–617; C do-
main, residues 629–732) cloned in pGex-4T3 (Pharmacia Biotech) and
pFLAG-CMV 6c (Sigma) were expressed in BL-21 E. coli and purified from
the GST frame by overnight thrombin (1 U/ml) cleavage, as described (For-
tugno et al., 2003).
Molecular dynamics simulations and docking procedures
The experimental setup for shepherdin computational modeling and dock-
ing to Hsp90 is available in the Supplemental Data.465
A R T I C L EAffinity chromatography and immunoprecipitation
Five mg of survivin peptide I74–L87 carrying an extra cysteine at the N
terminus was coupled to 1 ml of Sulfolink coupling gel (Pierce cat n. 20401),
as recommended by the manufacturer. To avoid binding to the internal cys-
teine (C84), this residue was blocked with an Acm group during the synthe-
sis. The block was removed after the binding to the resin by incubation in
10% AcOH, 15 M mercuric acetate (III), 0.2% β-mercaptoethanol for 6 hr
at 22°C. The resin was washed with 16 volumes of 1 M NaCl, and blocked
in 10 volumes of 1% BSA overnight at 4°C. 1 x 108 Raji cells were collected,
washed once in ice-cold TBS, suspended in 4 ml of lysis buffer (25 mM
Hepes [pH 7.4], 100 mM KCl, 2 mM EGTA, 1% Triton-X100, 50 mM NaF, 10
mM Na3VO4, plus protease inhibitors), and passed trough a 26-gauge
needle three times. An S100 fraction was obtained by centrifugation at
100,000 × g for 30 min at 4°C. The cleared lysate (10 mg/ml) was loaded
on the survivin peptide resin or an empty resin as control. After washes in
lysis buffer, proteins were eluted in 2% SDS, 20 mM Tris (pH 7.5). Samples
were separated onto a 12% SDS gel, and analyzed by Western blotting.
For peptide competition of Hsp90-ATP interaction (Marcu et al., 2000), three
g of recombinant Hsp90 N domain (1–272) was incubated with 10 mM
ATP, shepherdin, or scrambled peptide (150 M) in 200 l of molybdate
buffer containing 10 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 10 mM NAMoO4,
and 0.2% Tween 20 for 2 hr at 4°C under constant agitation. Samples were
further incubated with 50 l of γ-phosphate-linked ATP-sepharose (Boca
Scientific) for 2 hr at 4°C and washed, and bound material was eluted in
5% SDS and analyzed by Western blotting. In other experiments, Raji or
PBMC cells were lysed in 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5%
deoxycholate, 1% Triton X-100 plus protease inhibitors, and extracts (200
g) were applied to shepherdin-sepharose (5 mg/ml of resin, 0.5 ml) and
incubated for 1 hr at 4°C. Bound material was eluted with glycine (pH 2.5)
and analyzed by Western blotting or silver staining. A functional survivin-
Hsp90 complex was reconstituted in a cellular context using rabbit reticulo-
cyte extracts (Morishima et al., 2000). Aliquots of reticulocyte extracts (35
l in a total volume of 70 l) were left untreated or incubated with shep-
herdin or control peptide (150 M) for 3 hr at 22°C, mixed with recombinant
survivin (1 g) for 1 hr at 22°C, and immunoprecipitated with control IgG or
an antibody to Hsp90. The immune complexes were precipitated with pro-
tein G slurry, washed, and probed with antibodies to Hsp90 or survivin by
Western blotting.
Protein binding studies
Mutagenesis of the Hsp90 N domain was carried out by PCR, and individual
Ala substitutions of N51, S52, D93, D102, N106, S113, and F138 were con-
firmed by DNA sequencing. Wild-type or mutant Hsp90 constructs were
expressed as recombinant fusion proteins in BL-21 E. coli, and the GST
frame was released by overnight thrombin cleavage (Fortugno et al., 2003).
Shepherdin or scrambled peptide (100 g/ml) was immobilized on plastic
microtiter plates, incubated with recombinant Hsp90 (1 g/ml) or equal con-
centrations of N domain Hsp90 mutants (5 g/ml), and further mixed with
an antibody to Hsp90 (1 g/ml). Alternatively, shepherdin or scrambled pep-
tide (0.03–1 mg/ml) was immobilized on plastic microtiter plates, and further
incubated with 1 g/ml of recombinant N- or C-domain of Hsp90 for 1 hr
at 37°C. In all experiments, wells were washed 10 times, and binding of the
primary antibody was revealed by addition of biotin-conjugated rabbit anti-
mouse IgG for 1 hr at 37°C, followed by streptavidine-alkaline phosphatase
and determination of absorbance at A405 using p-nitrophenyl phosphate
(Zymed Laboratories, CA) as substrate (Fortugno et al., 2003). An antibody
specific for the Hsp90 N domain was purchased from Santa Cruz. A C
domain-specific antibody was from BD Transduction.
Cell death assays and analysis of Hsp90 function
Cell viability of various cell lines treated with cell-permeable shepherdin,
shepherdin-RV, their control scrambled peptides, or 17-AAG (Calbiochem)
was determined by an MTT assay (Sigma, MO) using 200,000 cells/ml (50
l), or, alternatively, by Trypan blue exclusion. In some experiments, HeLa
cells were transduced with an adenovirus encoding Bcl-2 at multiplicity of
infection of 50, treated with increasing concentrations of cell-permeable
shepherdinAtp or control cell-permeable scrambled peptide, and analyzed
by MTT after 12 hr. For determination of apoptosis, peptide-treated cultures
were simultaneously analyzed for caspase activity and propidium iodide (PI)
staining using CaspaTag (Intergen), or, alternatively, for Annexin V labeling466and PI staining, by multiparametric flow cytometry. Mitochondrial release of
cytochrome c was assessed in isolated cytosolic extracts of HeLa cells
incubated with 150 M shepherdinAtp or scrambled peptide, by Western
blotting. To monitor changes in Hsp90 client protein levels, PC3 cells
treated with shepherdinAtp or scrambled peptide (100 M) were harvested
after 16 hr, solubilized in lysis buffer (0.01% NP40, 10 mM Tris [pH 7.5], 50
mM KCl, 5 mM MgCl2, 2 mM DTT, 20% glycerol plus protease inhibitors)
plus four pulses on a sonicator (10 s each) at 50 J/Watt-sec, alternated by
30 s intervals on ice, and analyzed by Western blotting. Alternatively, PC3
lysates were immunoprecipitated with a rabbit polyclonal antibody to Hsp90
(Santa Cruz) precoupled to 8 l of a 50% slurry of protein-G-agarose beads
for 1 hr at 4°C. After washes, the immune complexes were analyzed for
telomerase activity by telomeric repeat amplification protocol (TRAP) assay
using the TRAPeze kit (Intergen, UK). Each reaction product was amplified
in the presence of a 36 bp internal TRAP assay standard (ITAS). TSR8 (R8)
quantitation standard (which serves as a standard to estimate the amount
of product extended by telomerase in a given extract) was included for each
set of TRAP assay.
CD34+ hematopoietic stem cell colony formation assay
The experiments were carried out as described previously (Pisarev et al.,
2003). Briefly, human CD34+ hematopoietic progenitor cells were isolated
from buffy coats of normal healthy volunteers using a magnetic bead sepa-
ration system (Miltenyi Biotec, Auburn, CA), and incubated with increasing
concentrations of shepherdinAtp or scrambled peptide for 2.5 hr at 37°C.
CD34+ cells were plated in duplicates into 6-well plates (5,000 cells per
well) in 2.5 ml of methylcellulose medium MethoCult GF H4434 (Stem Cell
Technologies, Vancouver, Canada), containing cytokines supporting growth
of myeloid and erythroid colonies. Colonies were scored on day 10–12.
Xenograft tumor models
All experiments involving animals were approved by an Institutional Animal
Care and Use Committee. For in vivo adaptation, 2.5 × 106 MCF-7 cells
were injected into the flanks of CB-17 SCID/beige mice (Taconics), and
grown as solid tumors for 2 weeks. Tumors were excised and minced under
sterile conditions, and the derived cell suspension was plated in complete
growth media, maintained in a 5% CO2 humidified incubator at 37°C, and
used for further xenograft tumor formation without estrogen supplementa-
tion. PC3 or in vivo adapted MCF-7 cells (2.5 × 106) were injected into the
flanks of CB17 SCID/beige mice, and allowed to form palpable solid tumors
for 6–7 days. When tumors reachedw35–70 mm3 in volume, animals were
randomized in 2 groups (4/6 animals/group for PC3 xenografts, and 6 ani-
mals/group for in vivo adapted MCF-7 xenografts), and administered saline
or shepherdin-RV at 50 mg/kg/daily for 11 consecutive days as i.p. injec-
tions (200 l/injection). In a second MCF-7 experiment, animals were
treated with saline or shepherdin (50 mg/kg/daily i.p.) for 23 consecutive
days from inoculation. In all experiments, tumor measurements were taken
daily with a caliper, and tumor volume was calculated according to the for-
mula 1/2 (length [mm]) × (width [mm])2.
Toxicity profile
Animals carrying PC3 xenograft tumors were injected i.p. with saline or
shepherdin-RV, and sacrificed after 1 hr. The tumors were excised and
snap-frozen, and tissue sections were incubated with streptavidin-conju-
gated PE followed by fluorescence microscopy. Blood samples from ani-
mals carrying MCF-7 xenograft tumors and treated with saline or shep-
herdin-RV were obtained at the end of treatment (day 11, experiment 1).
Total cell blood counts were performed on a Heska Veterinary Hematology
System. Blood chemistry parameters were determined using the Abaxis
VetScan Comprehensive Diagnostic Profile. For histologic analysis, liver,
spleen, and lungs were removed from saline- or shepherdin-treated animals
carrying MCF-7 xenograft tumors at the end of treatment (day 11, experi-
ment 1). Organs were fixed in formalin and paraffin-embedded, and tissue
sections were stained with hematoxylin/eosin and analyzed by light micro-
scopy. Alternatively, MCF-7 breast cancer xenograft tumors were excised
at the end of saline or shepherdin treatment (day 23, experiment 2), forma-
lin-fixed, embedded in paraffin, and processed for immunohistochemistry
with antibodies against survivin or Akt, according to published protocols
(Dohi et al., 2004). In all experiments, a nonbinding IgG was substituted as
a primary antibody, and gave no immunoreactivity. In other experiments,CANCER CELL : MAY 2005
A R T I C L EMCF-7 tumors extracted at the end of treatment from the shepherdin or
saline group were solubilized, and analyzed by Western blotting with anti-
bodies to survivin or Akt.
Statistical analysis
Data were analyzed using the two-sided unpaired t test on a GraphPad
software package for Windows (Prism). A p value of 0.05 was considered
as statistically significant.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/5/457/DC1/.
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